Effrosyni Georgiadou1, Helen Marketou2, George Trovas3, Ismene Dontas3, Nikolaos Papaioannou3, Konstantinos Makris2, Antonios Galanos3, Athanasios Papavassiliou4. 1. Th. Garofalidis Laboratory for Research of the Musculoskeletal System, Medical School, National & Kapodistrian University of Athens egeorgiadou@efet.gr. 2. Department of Biochemistry, KAT Hospital, Athens, Greece. 3. Th. Garofalidis Laboratory for Research of the Musculoskeletal System, Medical School, National & Kapodistrian University of Athens. 4. Department of Biological Chemistry, Medical School, National & Kapodistrian University of Athens, Athens, Greece.
Abstract
AIM: To evaluate the short-term effects of calcitriol and sevelamer hydrochloride on fibroblast growth factor-23 (FGF23) in humans and to determine whether the effect is direct or indirect through calcitriol-induced increased absorption of phosphorus from the intestine. PATIENTS AND METHODS: A total of 15 healthy individuals were tested at three time points and stages, for 24 h and at 1-week intervals. During each stage, blood samples were taken at three time points (0, 8 and 24 h); baseline stage: under no intervention; second stage, while receiving 0.5 μg calcitriol orally twice daily; and at the third stage, while receiving 0.5 μg calcitriol orally twice daily and sevelamer hydrochloride during meals. The changes in FGF23, parathyroid hormone, calcitriol, Ca, and phosphorus were determined. RESULTS: During calcitriol administration, the FGF23 level changed significantly (p=0.008), with the level at 24 h levels being significantly higher than at 8 h (8.8 pg/ml vs. 13.0 pg/ml, p=0.036). There was a statistically significant difference in the percentage change, among the three stages, at time 8 to 24 h and 0 to 24 h for FGF23 (p=0.014 and p=0.015, respectively), with significant differences between baseline vs. calcitriol for 8 to 24 h FGF23 change (-9.23% vs. 26.98%, p=0.003) and a trend between baseline vs. calcitriol (p=0.061) and calcitriol plus sevelamer (p=0.069) for 0 to 24 h FGF23 change. CONCLUSION: Administration of calcitriol to healthy individuals increases the circulating level of FGF23 within 24 h. Combined calcitriol and sevelamer administration restrains the increase of FGF23, suggesting that calcitriol-induced increased absorption of phosphate from the intestine might also be involved in the increase of FGF23. Copyright
AIM: To evaluate the short-term effects of calcitriol and sevelamer hydrochloride on fibroblast growth factor-23 (FGF23) in humans and to determine whether the effect is direct or indirect through calcitriol-induced increased absorption of phosphorus from the intestine. PATIENTS AND METHODS: A total of 15 healthy individuals were tested at three time points and stages, for 24 h and at 1-week intervals. During each stage, blood samples were taken at three time points (0, 8 and 24 h); baseline stage: under no intervention; second stage, while receiving 0.5 μg calcitriol orally twice daily; and at the third stage, while receiving 0.5 μg calcitriol orally twice daily and sevelamer hydrochloride during meals. The changes in FGF23, parathyroid hormone, calcitriol, Ca, and phosphorus were determined. RESULTS: During calcitriol administration, the FGF23 level changed significantly (p=0.008), with the level at 24 h levels being significantly higher than at 8 h (8.8 pg/ml vs. 13.0 pg/ml, p=0.036). There was a statistically significant difference in the percentage change, among the three stages, at time 8 to 24 h and 0 to 24 h for FGF23 (p=0.014 and p=0.015, respectively), with significant differences between baseline vs. calcitriol for 8 to 24 h FGF23 change (-9.23% vs. 26.98%, p=0.003) and a trend between baseline vs. calcitriol (p=0.061) and calcitriol plus sevelamer (p=0.069) for 0 to 24 h FGF23 change. CONCLUSION: Administration of calcitriol to healthy individuals increases the circulating level of FGF23 within 24 h. Combined calcitriol and sevelamer administration restrains the increase of FGF23, suggesting that calcitriol-induced increased absorption of phosphate from the intestine might also be involved in the increase of FGF23. Copyright
Authors: Y Nishida; Y Taketani; H Yamanaka-Okumura; F Imamura; A Taniguchi; T Sato; E Shuto; K Nashiki; H Arai; H Yamamoto; E Takeda Journal: Kidney Int Date: 2006-10-25 Impact factor: 10.612
Authors: Sherri -Ann M Burnett; Samantha C Gunawardene; F Richard Bringhurst; Harald Jüppner; Hang Lee; Joel S Finkelstein Journal: J Bone Miner Res Date: 2006-08 Impact factor: 6.741
Authors: Michael T Collins; John R Lindsay; Alka Jain; Marilyn H Kelly; Carolee M Cutler; Lee S Weinstein; Jie Liu; Neal S Fedarko; Karen K Winer Journal: J Bone Miner Res Date: 2005-07-18 Impact factor: 6.741
Authors: Pablo Florenzano; Macarena Jimenez; Carlos R Ferreira; Galina Nesterova; Mary Scott Roberts; Sri Harsha Tella; Luis Fernandez de Castro; Rachel I Gafni; Myles Wolf; Harald Jüppner; Barbara Gales; Katherine Wesseling-Perry; Daniela Markovich; William A Gahl; Isidro B Salusky; Michael T Collins Journal: J Am Soc Nephrol Date: 2020-07-06 Impact factor: 10.121
Authors: Aisanjiang Wubuli; Christian Gerlinger; Henry Reyer; Michael Oster; Eduard Muráni; Nares Trakooljul; Siriluck Ponsuksili; Petra Wolf; Klaus Wimmers Journal: BMC Genomics Date: 2020-09-11 Impact factor: 3.969